Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4227117 | 0.98 | DPP4 (0.46) | DPP4KDM1AMAOAMAOBOPRM1 | |
| SCHEMBL17455848 | 0.98 | DPP4 (0.44) | DPP4KDM1AMAOAMAOBOPRM1 | |
| SCHEMBL2874112 | 0.98 | DPP4 (0.44) | DPP4KDM1AMAOAMAOBOPRM1 | |
| SCHEMBL2874108 | 0.98 | DPP4 (0.44) | DPP4KDM1AMAOAMAOBOPRM1 | |
| Hydrochloric Acid SCHEMBL3097237 | 0.95 | DPP4 (0.43) | DPP4KDM1AMAOAMAOBOPRM1 | |
| Hydrochloric Acid SCHEMBL16055400 | 0.95 | DPP4 (0.43) | DPP4KDM1AMAOAMAOBOPRM1 | |
| Hydrochloric Acid SCHEMBL16054227 | 0.95 | DPP4 (0.43) | DPP4KDM1AMAOAMAOBOPRM1 | |
| Hydrochloric Acid SCHEMBL16054225 | 0.95 | DPP4 (0.43) | DPP4KDM1AMAOAMAOBOPRM1 | |
| Hydrochloric Acid SCHEMBL3097228 | 0.95 | DPP4 (0.43) | DPP4KDM1AMAOAMAOBOPRM1 | |
| SCHEMBL2552594 | 0.93 | KDM1A (0.41) | DPP4KDM1AMAOAMAOBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-1945606-A1 | ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF | Korea Research Institute of Chemical Technology (KR) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007052938-A1 | ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-05-10 | — | — | WO | disclosed |
| US-4323503-A | PSYCHOFUNCTION PROPERTIES SUCH AS ANXIOLYTIC OR PSYCHOSTIMULANT | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1982-04-06 | — | — | US | disclosed |
| US-4248885-A | FOR GASTROINTESTINAL, UROGENITAL, RHEUMATIC, AND CARDIOVASCULAR DISEASE | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1981-02-03 | — | — | US | disclosed |
| US-4186135-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1980-01-29 | — | — | US | disclosed |
| US-4087428-A | ANTIEMETICS | A. H. ROBINS COMPANY, INC. (US) | 1978-05-02 | — | — | US | disclosed |
| US-4073796-A | ANTIEMETIC | A. H. ROBINS COMPANY, INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
| US-4039678-A | N-(SUBSTITUTED-3-PYRROLIDINYL)-1-NAPHTHALENE CARBOXAMIDES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-08-02 | — | — | US | disclosed |
| US-4005208-A | GASTRIC JUICE, ANTISECRETORY | SMITHKLINE CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
| US-4002757-A | ANTIEMETIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
| US-3966957-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-29 | — | — | US | disclosed |
| US-3963745-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | DPP4 1742/4885KDM1A 3238/4885MAOA 2857/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | DPP4 1361/4885KDM1A 76/4885MAOA 2403/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | DPP4 1742/4885KDM1A 3238/4885MAOA 2857/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | DPP4 2136/4885KDM1A 2923/4885MAOA 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.